In contrast, the pharmacological inhibition of RIPK1 to prevent necroptosis results in neuroprotection in preclinical AD models [4], suggesting that targeting cell death remains a potentially viable therapeutic strategy for AD. This evidence concerns the gene RIPK1 and Alzheimer disease.